KAILERA THERAPEUTICS INC
KLRANASDAQ🏆 #2011 by market capEarnings Nov 4US Equity
$13.40▼ $0.02 (−0.15%)
Market closed · at closeTrack KLRA
Get earnings, price moves & breaking news on Telegram
24h▼ 0.1%
7d▲ 4.3%
14d▲ 19.2%
30d▲ 17.2%
ytd—
1y—
🏦Market Cap
$1.74B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $13.31 – $13.80
- 52-Week Range
- $9.76 – $28.23
- Volume (shares)
- 57,192
- Avg Volume (shares)
- —
- Shares Outstanding
- 129.6M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
KAILERA THERAPEUTICS INC
KLRAFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout KAILERA THERAPEUTICS INC
Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
12 analysts
Strong Buy5
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.